Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Helus Pharma Inc. (HELP) is the issuer whose shares OrbiMed Advisors LLC and OrbiMed Capital LLC reported beneficially owning; September 30, 2026 is listed as the event date. OrbiMed Advisors reported 496,265 shares (0.7%), while OrbiMed Capital reported 847,910 shares (1.2%).
The two entities also stated that, on behalf of other persons, they hold 1.8% of the shares of Common Stock issuable upon exercise of warrants.
Key Figures
Beneficial ownership — OrbiMed Advisors LLC:496,265 sharesBeneficial ownership — OrbiMed Capital LLC:847,910 sharesWarrant-issuable Common Stock held on behalf of others:1.8%
3 metrics
Beneficial ownership — OrbiMed Advisors LLC496,265 shares0.7% of the class; event date September 30, 2026
Beneficial ownership — OrbiMed Capital LLC847,910 shares1.2% of the class; event date September 30, 2026
Warrant-issuable Common Stock held on behalf of others1.8%Reported by OrbiMed Advisors LLC and OrbiMed Capital LLC in the aggregate
Key Terms
beneficial ownership, Shared Voting Power, Sole Dispositive Power, shares of Common Stock issuable upon the exercise of warrants
4 terms
beneficial ownershipregulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared Voting Powerregulatory
"Shared Voting Power 496,265.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Sole Dispositive Powerregulatory
"Sole Dispositive Power 847,910.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
shares of Common Stock issuable upon the exercise of warrantsfinancial
"shares of Common Stock issuable upon the exercise of warrants"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many HELP shares did OrbiMed Advisors and OrbiMed Capital report owning?
OrbiMed Advisors LLC reported beneficial ownership of 496,265 shares (0.7%), and OrbiMed Capital LLC reported 847,910 shares (1.2%). The event date is September 30, 2026.
Who had voting and dispositive power over the HELP shares reported by OrbiMed?
OrbiMed Advisors LLC reported shared voting and dispositive power over its 496,265 shares. OrbiMed Capital LLC reported sole voting and dispositive power over its 847,910 shares.
Who exercised power over the warrant-issuable HELP shares reported by OrbiMed?
The entities said a management committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu exercises investment and voting power over the shares issuable upon warrant exercise. Each committee member disclaims beneficial ownership of those shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Helus Pharma Inc.
(Name of Issuer)
Common Stock, no par value
(Title of Class of Securities)
423492107
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
423492107
1
Names of Reporting Persons
ORBIMED ADVISORS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
496,265.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
496,265.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
496,265.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.7 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
423492107
1
Names of Reporting Persons
ORBIMED CAPITAL LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
847,910.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
847,910.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
847,910.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Helus Pharma Inc.
(b)
Address of issuer's principal executive offices:
100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9
Item 2.
(a)
Name of person filing:
OrbiMed Advisors LLC
OrbiMed Capital LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor
New York, NY 10022
(c)
Citizenship:
Please refer to Item 4 on each cover sheet for each filing person.
(d)
Title of class of securities:
Common Stock, no par value
(e)
CUSIP No.:
423492107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
OrbiMed Advisors LLC: 496,265
OrbiMed Capital LLC: 847,910
(b)
Percent of class:
OrbiMed Advisors LLC: 0.7%
OrbiMed Capital LLC: 1.2%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 847,910
(ii) Shared power to vote or to direct the vote:
OrbiMed Advisors LLC: 496,265
OrbiMed Capital LLC: 0
(iii) Sole power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 847,910
(iv) Shared power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 496,265
OrbiMed Capital LLC: 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Persons hold 1.8% of the shares of Common Stock issuable upon the exercise of warrants in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock issuable upon the exercise of warrants through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock issuable upon the exercise of warrants reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.